Study of rezpegaldesleukin for moderate to severe eczema
Part of Immune system & allergy, Skin clinical trials.
This study tests an experimental medicine (rezpegaldesleukin) for people with moderate to severe eczema. It aims to see if the drug can calm the immune system and improve skin symptoms when other treatments haven't worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 12 years old and weigh at least 40 kg (about 88 pounds).
- You have had eczema for at least 12 months and it is moderate to severe (covering at least 10% of your body).
- Your eczema score (EASI) is 16 or higher, which means it's significant.
- You have tried prescription creams but they didn't help enough, or you couldn't use them.
- You cannot have started certain treatments before this study, like other injected biologic drugs or JAK inhibitors.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called rezpegaldesleukin for people aged 12 and older with moderate-to-severe atopic dermatitis (eczema) that hasn't improved enough with topical treatments. The goal is to see if it can safely reduce eczema symptoms.
This trial tests an investigational drug called AK139, given as an injection, for people with moderate-to-severe atopic dermatitis (eczema). The goal is to reduce itching and clear skin better than current topical treatments.
This study tests a new medication called HXN5003 to see if it is safe and how well it works for people with moderate-to-severe eczema (atopic dermatitis). It may help reduce symptoms like itching and rash.
This trial tests a study drug (PF-08049820) for people with moderate to severe eczema who haven't found a suitable prescription treatment. It aims to see if the drug can improve skin symptoms and itching.
This study tests an experimental treatment for people with moderate to severe eczema that has lasted at least a year. It aims to see if the new medicine can help control symptoms better than current options.
This study tests an investigational drug (SIM0278) given as an injection to see if it helps reduce eczema symptoms. It is for people with moderate to severe atopic dermatitis who have not used certain other treatments recently.
Hear when a new Moderate to Severe Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.